ATE109008T1 - T-zellen-epitope als träger für einen konjugierten impfstoff. - Google Patents

T-zellen-epitope als träger für einen konjugierten impfstoff.

Info

Publication number
ATE109008T1
ATE109008T1 AT89908669T AT89908669T ATE109008T1 AT E109008 T1 ATE109008 T1 AT E109008T1 AT 89908669 T AT89908669 T AT 89908669T AT 89908669 T AT89908669 T AT 89908669T AT E109008 T1 ATE109008 T1 AT E109008T1
Authority
AT
Austria
Prior art keywords
conjugates
epitopes
cell epitopes
carriers
conjugated vaccine
Prior art date
Application number
AT89908669T
Other languages
English (en)
Inventor
Garvin Bixler
Subramonia Pillai
Richard Insel
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Application granted granted Critical
Publication of ATE109008T1 publication Critical patent/ATE109008T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Couplings Of Light Guides (AREA)
AT89908669T 1988-02-01 1989-01-31 T-zellen-epitope als träger für einen konjugierten impfstoff. ATE109008T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15068888A 1988-02-01 1988-02-01

Publications (1)

Publication Number Publication Date
ATE109008T1 true ATE109008T1 (de) 1994-08-15

Family

ID=22535596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89908669T ATE109008T1 (de) 1988-02-01 1989-01-31 T-zellen-epitope als träger für einen konjugierten impfstoff.

Country Status (10)

Country Link
EP (1) EP0399001B1 (de)
JP (1) JP2921574B2 (de)
AT (1) ATE109008T1 (de)
AU (1) AU634153B2 (de)
CA (2) CA1340956C (de)
DE (1) DE68917126T2 (de)
DK (1) DK174416B1 (de)
FI (1) FI104374B (de)
NO (1) NO179164C (de)
WO (1) WO1989006974A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5500366A (en) * 1990-09-18 1996-03-19 Biotech Australia Pty. Ltd. Polynucleotide encoding T-cell epitopes of the protein TraT
WO1993011157A1 (en) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX)
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL106436A0 (en) * 1992-07-22 1993-11-15 Proteus Molecular Design Synthetic polypeptides and their use
ATE174628T1 (de) * 1992-07-31 1999-01-15 Medeva Holdings Bv Expression rekombinanter fusionsproteine in attenuierten bakterien
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
DK140992D0 (da) * 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
CA2168459C (en) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
US5725860A (en) * 1994-03-07 1998-03-10 Auckland Uniservices Limited Method for reducing the risk of developing diabetes
ATE362380T1 (de) * 1995-03-31 2007-06-15 Xenova Res Ltd Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
ES2180045T3 (es) 1996-04-19 2003-02-01 Us Gov Sec Health Peptidos ras mutados para la generacion de linfocitos t citotoxicos cd8+.
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US6663861B2 (en) 2000-11-09 2003-12-16 Antibodyshop A/S Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
EP2356133B1 (de) 2008-10-10 2019-07-31 Zera Intein Protein Solutions, S.L. Rekombinante proteinkörper als immunogenspezifische adjuvansien
JP5841044B2 (ja) * 2009-03-23 2016-01-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 複合糖質ワクチン
EP2418284A1 (de) 2010-08-13 2012-02-15 ERA Biotech, S.A. Polypeptidsequenzen zur Induzierung von Proteinkörpern
EP2870974A1 (de) * 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
DK3817775T3 (da) 2018-07-04 2024-09-16 Vaxcyte Inc Forbedringer i immunogene konjugater
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
DE68917126D1 (de) 1994-09-01
AU634153B2 (en) 1993-02-18
DK182990D0 (da) 1990-07-31
WO1989006974A2 (en) 1989-08-10
NO902909L (no) 1990-08-27
JPH03502691A (ja) 1991-06-20
FI104374B (fi) 2000-01-14
DE68917126T2 (de) 1995-02-02
CA1340958C (en) 2000-04-11
DK182990A (da) 1990-07-31
AU3065489A (en) 1989-08-25
JP2921574B2 (ja) 1999-07-19
FI903292A0 (fi) 1990-06-29
NO179164C (no) 1996-08-21
EP0399001A1 (de) 1990-11-28
DK174416B1 (da) 2003-02-17
NO902909D0 (no) 1990-06-29
EP0399001B1 (de) 1994-07-27
NO179164B (no) 1996-05-13
WO1989006974A3 (en) 1989-08-24
CA1340956C (en) 2000-04-11

Similar Documents

Publication Publication Date Title
ATE109008T1 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
IL104696A0 (en) Dual carrier immunogenic construct and a vaccine containing the same
DK1089760T3 (da) Kunstige T-hjælpecelleepitoper som immunstimulatorer for syntetiske peptidimmunogener
WO1998058668A3 (en) Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
PT1135166E (pt) Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina
DE69839587D1 (de) Enterokokkus antigene und vakzine
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
EP0699907A3 (de) Diagnoseverfahren, lösliches CD8-T-Zelloberflächenantigen und anti-CD8-Antikörper
DE3380053D1 (en) Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them
NO974727L (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
IL76271A0 (en) Cross-reactive and protective epitopes of circumsporozoite proteins
CO5241277A1 (es) Vacuna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee